^
    Back
    Association details:
    Biomarker:POLE mutation
    Cancer:Colorectal Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

    Excerpt:
    ...Mismatch repair deficient or microsatellite instable (defined below), or POLE mutated tumors A....
    Trial ID:
    NCT03435107
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Int J Cancer
    Title:

    Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer

    Published date:
    02/18/2022
    Excerpt:
    The progression-free survival rate of 12 months was 58.2% (95% CI: 39.0-73.1) and the 12-month overall survival rate was 68.3% (95% CI: 48.8-81.7)…. In conclusion, durvalumab showed promising clinical activity with encouraging response rates and satisfactory survival outcomes in mCRC patients with MSI-H/dMMR or POLE EDM.
    DOI:
    https://doi.org/10.1002/ijc.33966